



SPARC/Sec/SE/2021-22/83

January 12, 2022

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

Sub: Announcement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)

Pursuant to Regulation 30 of the Listing Regulations, we hereby inform that the Company has received an intimation from the partner that SPARC is eligible to receive US\$ 5 million upon achieving the regulatory milestones for the program developed using SPARC technology.

Pursuant to the agreement entered between the parties, SPARC shall also be eligible for additional future milestones and royalties on net sales.

This is for your information and dissemination.

Yours faithfully,

For **Sun Pharma Advanced Research Company Ltd.**

Dinesh Lahoti
Company Secretary and Compliance Officer
ICSI Membership No. A22471